BridgeBio Oncology Therapeutics, Inc. (BBOT)

BBOT Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	31.52	30.85	0.25
Short-Term Investments	99.88	124.78	-
Cash & Short-Term Investments	131.4	155.63	0.25
Cash Growth	-	62152.40%	-
Other Receivables	1.08	0.08	1.72
Receivables	1.08	0.08	1.72
Prepaid Expenses	4.3	2.98	1.96
Total Current Assets	142.35	158.69	3.94
Property, Plant & Equipment	3.45	0.49	0.6
Other Long-Term Assets	5.46	5.12	1.41
Total Assets	151.25	164.3	5.94
Accounts Payable	2.2	3.07	0.58
Accrued Expenses	24.4	12.92	3.54
Other Current Liabilities	0.33	3.59	12.66
Total Current Liabilities	27.25	19.58	16.78
Total Liabilities	29.77	19.58	16.78
Additional Paid-In Capital	45.23	43.54	32.61
Retained Earnings	-273.01	-222.52	-148.25
Comprehensive Income & Other	0.05	0.35	-
Total Common Equity	-227.73	-178.64	-115.64
Shareholders' Equity	121.49	144.72	-10.83
Total Liabilities & Equity	151.25	164.3	5.94
Net Cash (Debt)	128.56	155.63	0.25
Net Cash Growth	-	62152.40%	-
Net Cash Per Share	394.59	1072.39	2.00
Filing Date Shares Outstanding	0.56	0.32	0.12
Total Common Shares Outstanding	0.56	0.32	0.12
Working Capital	115.1	139.11	-12.84
Book Value Per Share	-403.34	-558.92	-927.16
Tangible Book Value	-227.73	-178.64	-115.64
Tangible Book Value Per Share	-403.34	-558.92	-927.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.